TAC新辅助化疗方案治疗三阴性乳腺癌的疗效及预后

摘要/Abstract

摘要： 【摘要】目的探讨TAC新辅助化疗方案治疗三阴性乳腺癌（triple-negative breast cancer，TNBC）的临床疗效。方法对接受4～6个周期TAC新辅助化疗方案治疗的63例TNBC进行回顾性研究，分析近远期化疗疗效。结果 63例患者总有效率(RR)96.83%，其中完全缓解(CR)57.14%（36/63)，部分缓解(PR)39.68%(25/63）。主要不良反应中性粒细胞减少36例（57.14%），中性粒细胞减少性发热25例（39.68%），恶心呕吐33例（52.38%），腹泻14例（22.22%），口腔黏膜炎13例（20.63%），乏力虚弱10例（15.87%）。术后死亡7例，局部复发8例，远处转移21例，3年生存率88.89%。结论应用TAC新辅助化疗方案能提高TNBC治疗效果，改善患者生活质量，提高3年生存率。

关键词: TAC方案, 三阴性乳腺癌, 新辅助化疗

Abstract: Objective To study the curative effect of neoadjuvant chemotherapy of TAC in the treatment of triple-negative breast cancer. Methods To accept 4～6 cycles TAC neoadjuvant chemotherapy of 63 cases of TNBC were retrospectively study. Analysis the near-term and long-term curative effects. Results Of the 63 patients,the overal response rate(RR) was 96.83%, including complete response(CR) was 57.14%（36/63)，partial response(PR) was 39.68%(25/63）；the major complications included neutropenia（57.14%）,nertropenia associated fever（39.68%）,nausea and vomiting（52.38%）,diarrhea（22.22%）,oral mucositis （20.63%）,malaise and weakness（15.87%）.Postoperative death was 7 cases，There were 8 cases of local recurrence and 21 cases of remote metastasis. The overall 3-year survival rate was 88.89%. Conclusion TAC neoadjuvant chemotherapy could improve the curative effect of TNBC with better quality of life and promoted 3-year survival rate.

Key words: TAC, Triple negative breast cancer, Neoadjuvant chemotherapy

吴恢升何劲松陈伟财王媛王先明. TAC新辅助化疗方案治疗三阴性乳腺癌的疗效及预后[J]. 岭南现代临床外科, 2012, 12(03): 187-189.

参考文献

参考文献
[1] 马静.三阴乳腺癌的最新治疗进展[J].中国肿瘤临床,2011,38(19):1234-1238.
[2] Dent R,Trudeau M,Pritchard KI，et al.Triple-negative breast cancer: clinical features and patterns of recurrence.Clin.Cancer Res.2007;13;4429–4434.
[3] Tischkowitz M,Brunet JS,Begin LR et al.Use of immunohistochemical markers can refine prognosis in triple negative breast cancer.BMC Cancer 2007;7;134.
[4] Bauer KR, Brown M, Cress RD,et al.Descriptive analysis of estrogen receptor (ER)-negative,progesterone receptor (PR)-negative,and HER2-negative invasive breast cancer,the so-called triple-negative phenotype: a population-based study from the California cancer Registry.Cancer 2007;109;1721–1728.
[5] 袁中玉，王树森，高岩，等.305例三阴乳腺癌患者的临床特征及预后因素分析。癌症，2008，27（6）：561-565.
[6] Carey LA,Dees EC,Sawyer L,et al: The triple negative paradox: Primary tumor chemosensitivity of breast cancer subtypes.Clin Cancer Res,2007;13:2329-2334.
[7] Fulford LG,Easton DF,Reis-Filho JS,et al.Specific morphological features predictive for the basal phenotype in grade 3 invasive ductal carcinoma of breast.Histopathology 2006;49;22–34.
[8] Rakha EA,El-Sayed ME,Green AR，et al.Prognostic markers in triple-negative breast cancer.Cancer 2007;10 25–32.
[9] Uhm JE,Park YH,Yi SY,et al.Treatment outcomes and clinicopathologic characteristics of triple–negative breast cancer patients who received platinum–containing chemotherapy.Int J Cancer,2009,124(6):1457～1462.
[10] 王锡宏，余继海，陈炯。新辅助化疗在乳腺癌保乳治疗中的价值。中国临床保健杂志，2008,11（1）：103～105.
[11] Liedtke C,Mazou ni C Hess KR, et al.Response to neoadjuvant therapy and long–term survival in patients with triple–negative breast cancer.J Clin Oncol,2008,26(8):1275～1281
[12] Wang S,Yang H,Tong F,et al.Response to neoadjuvant therapy and disease free survival in patients with triple–negative breast cancer.Gan To Kagaku Ryoho,2009,36(2):255～258.
[13] 周波，谢菲，王思源，等。紫杉醇联合蒽环类的新辅助化疗方案治疗三阴乳腺癌的疗效及预后。中国癌症杂志，2009,19（2）：129～132.
[14] Dent R,Trudeau M,Pritcbard K,et al.Triple-nagative breast cancer.clinical features and patterns of recurrence[J].Clin Cancer Res,2007,13(15pt):4419-4434.
[15] 林坚，胡梅齐，彭炜，等。三阴性乳腺癌的临床病例特征及预后。中国癌症杂志，2010,20（6）：462～465.